CONNECT WITH US
HealthTech

HealthTech

American Cancer Society updates prostate cancer screening guideline: Regular PSA testing for average- and high-risk men

Medical Xpress logo

Published on

Add as a preferred source on Google
American Cancer Society updates prostate cancer screening guideline: Regular PSA testing for average- and high-risk men

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The American Cancer Society (ACS) today released an updated guideline for prostate cancer screening to help find cancer before it spreads and reduce the risk of dying from the disease. Key changes include a direct recommendation for prostate-specific antigen (PSA)-based screening every two years for average-risk men aged 50–69, with clinicians ensuring patients understand the potential benefits, limitations and harms before starting screening. Also, ACS recommends annual PSA-based screening beginning at 45 years old for Black men and men with a strong family history of prostate cancer.

Since the previous ACS guideline was published in 2010, there is stronger evidence showing that screening for prostate cancer with a PSA test significantly reduces prostate cancer mortality and diagnosis of advanced-stage disease. A PSA test is a simple blood test that measures the level of prostate-specific antigen. There have been advances in approaches to an elevated PSA that can reduce the risk of adverse outcomes associated with diagnosing and treating prostate cancer that may not be life-threatening. The guideline update is published in a report in CA: A Cancer Journal for Clinicians.

"PSA testing remains the cornerstone of detecting prostate cancer early, and we now have stronger evidence of its benefits," said Dr. Robert Smith, senior vice president, early cancer detection science, and director, Center for Early Cancer Detection at the American Cancer Society and senior author of the report.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.